GF Fund Management CO. LTD. Acquires 759 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GF Fund Management CO. LTD. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.4% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 31,801 shares of the biopharmaceutical company's stock after purchasing an additional 759 shares during the period. GF Fund Management CO. LTD.'s holdings in Regeneron Pharmaceuticals were worth $20,169,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of REGN. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the last quarter. TD Private Client Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after buying an additional 15 shares during the last quarter. Adirondack Trust Co. grew its position in shares of Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 18 shares in the last quarter. Prestige Wealth Management Group LLC increased its holdings in shares of Regeneron Pharmaceuticals by 23.2% in the 4th quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock valued at $72,000 after acquiring an additional 19 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after acquiring an additional 19 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $2.74 during trading hours on Friday, reaching $545.00. 456,413 shares of the company traded hands, compared to its average volume of 905,431. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The stock's fifty day moving average is $550.54 and its 200 day moving average is $627.29. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The stock has a market cap of $58.84 billion, a P/E ratio of 13.87, a price-to-earnings-growth ratio of 2.00 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the previous year, the business posted $9.55 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.65%. Regeneron Pharmaceuticals's payout ratio is presently 8.96%.

Analysts Set New Price Targets

Several analysts have weighed in on REGN shares. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. UBS Group lowered their price objective on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a research report on Thursday, June 5th. Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Finally, The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $822.58.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.